Berlin Cures announces start of Phase IIa for its DNA-based neutralizer of β1-adrenoceptor autoantibodies

Berlin Cures announces the start of the phase IIa trial for its β1-adrenoceptor autoantibody (β1-AAb) neutralizing ssDNA product BC 007. β1-AAbs have been identified as a relevant pathogenic cause of heart failure. BC 007 is now being tested as the first causative drug for patients with β1-AAb associated heart failure.   Heart failure is one … Continue reading Berlin Cures announces start of Phase IIa for its DNA-based neutralizer of β1-adrenoceptor autoantibodies